Baker J, Aliabadi N, Munjal I, Jiang Q, et al. Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 study. Vaccine 2024 Apr 13:S0264-410X(24)00387-6. doi: 10.1016/j.vaccine.2024.
PMID: 38616438